Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Product update

Reminyl skin reactions

The summary of product characteristics for the Alzheimer’s disease drug Reminyl (galantamine hydrobromide; Shire) has been updated to warn that serious skin reactions, including Stevens Johnson syndrome and acute generalized exanthematous pustulosis, have been reported in patients. Patients should be informed about the signs of serious skin reactions and Reminyl should be discontinued at the first appearance of skin rash.  

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200492

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.